Locoregional Recurrence and Survival Outcomes in Breast Cancer Treated With Modern Neoadjuvant Chemotherapy: A Contemporary Population-based Analysis

医学 乳腺癌 肿瘤科 内科学 紫杉烷 蒽环类 乳房切除术 放射治疗 化疗 保乳手术 三阴性乳腺癌 新辅助治疗 人口 癌症 环境卫生
作者
Sonja Murchison,Alan Nichol,Caroline Speers,Lovedeep Gondara,Nathalie LeVasseur,Caroline Lohrisch,Isabelle Vallières,Pauline T. Truong
出处
期刊:Clinical Breast Cancer [Elsevier BV]
卷期号:22 (7): e773-e787
标识
DOI:10.1016/j.clbc.2022.07.003
摘要

Data guiding radiotherapy (RT) decisions after neoadjuvant chemotherapy (NAC) is largely retrospective, based on older treatment approaches without molecular subtype information. This study evaluated outcomes in breast cancer patients treated with modern NAC by molecular subtype and locoregional treatment.There were 949 patients diagnosed between 2005 and 2016 treated with NAC followed by surgery ± locoregional radiotherapy (LRRT). Outcomes were 7-year locoregional relapse-free survival (LRRFS), breast cancer-specific survival (BCSS), and overall survival (OS).Median follow-up was 6.5 years, 92% had cT2-4 and 72% cN1-3 disease. Subtypes were: 21% Luminal A, 18% Luminal B, 35% Her2+, and 21% triple-negative breast cancer (TNBC). Combined taxane and anthracycline-based NAC was used in 91.7% of cases. All patients with Her2+ disease received anti-Her2 therapy. After NAC, the majority (84.9%) underwent mastectomy, and received LRRT (86.1%). Only 11% had mastectomy without RT. Pathologic complete response (pCR) rates were 2.5% for Luminal A, 14.4% Luminal B, 27% TNBC, and 35.1% Her2+. Overall, adjuvant LRRT was associated with improved outcomes but was most significant for improved LRRFS in TNBC (92.5% vs. 68.5%, P < .001; Her2+ 95.4% vs. 93.6%, P = .81; Luminal A 97.4% vs. 100%, P = .49; Luminal B 89.7% vs. 100%, P = .17). On multivariable analysis, factors associated with reduced LRRFS were grade 3 histology (HR 4.96, P = .009) and no pCR (HR 7.0, P = .0008). Predictors of lower BCSS and OS were age >50, grade 3, cT3-4, lack of pCR, LRRT omission, and TNBC and Her2+ subtypes.In this analysis of patients treated with modern NAC, pCR rates varied by molecular subtype. Patients who did not receive LRRT, particularly those with TNBC, had lower survival compared to those treated with LRRT. These findings support the need for prospective studies to evaluate the safety of de-escalating RT after NAC.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
PDF的下载单位、IP信息已删除 (2025-6-4)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
传奇3应助天真皓轩采纳,获得10
刚刚
上官若男应助科研通管家采纳,获得10
刚刚
刚刚
刚刚
刚刚
丘比特应助科研通管家采纳,获得10
刚刚
田様应助科研通管家采纳,获得10
刚刚
刚刚
丘比特应助科研通管家采纳,获得10
刚刚
刚刚
刚刚
1秒前
星辰大海应助完美的一天采纳,获得10
1秒前
NexusExplorer应助科研通管家采纳,获得20
1秒前
李健应助完美的一天采纳,获得10
1秒前
1秒前
Singularity应助完美的一天采纳,获得10
1秒前
JJun发布了新的文献求助10
1秒前
Jasper应助完美的一天采纳,获得10
1秒前
勤恳的浩阑完成签到,获得积分10
2秒前
4秒前
复杂慕蕊应助阿弥陀佛采纳,获得20
4秒前
小二郎应助兰天采纳,获得10
5秒前
老实的寒安完成签到,获得积分10
5秒前
6秒前
小五完成签到 ,获得积分10
7秒前
哇哇哇发布了新的文献求助10
7秒前
7秒前
8秒前
Maple发布了新的文献求助10
9秒前
ocean发布了新的文献求助10
10秒前
10秒前
10秒前
Wang发布了新的文献求助10
10秒前
11秒前
12秒前
噔噔蹬发布了新的文献求助10
13秒前
13秒前
hint完成签到 ,获得积分10
14秒前
小管完成签到,获得积分10
15秒前
高分求助中
The Mother of All Tableaux Order, Equivalence, and Geometry in the Large-scale Structure of Optimality Theory 2400
Ophthalmic Equipment Market by Devices(surgical: vitreorentinal,IOLs,OVDs,contact lens,RGP lens,backflush,diagnostic&monitoring:OCT,actorefractor,keratometer,tonometer,ophthalmoscpe,OVD), End User,Buying Criteria-Global Forecast to2029 2000
A new approach to the extrapolation of accelerated life test data 1000
Cognitive Neuroscience: The Biology of the Mind 1000
Cognitive Neuroscience: The Biology of the Mind (Sixth Edition) 1000
Optimal Transport: A Comprehensive Introduction to Modeling, Analysis, Simulation, Applications 800
Official Methods of Analysis of AOAC INTERNATIONAL 600
热门求助领域 (近24小时)
化学 材料科学 医学 生物 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 遗传学 基因 物理化学 催化作用 冶金 细胞生物学 免疫学
热门帖子
关注 科研通微信公众号,转发送积分 3959633
求助须知:如何正确求助?哪些是违规求助? 3505879
关于积分的说明 11126688
捐赠科研通 3237840
什么是DOI,文献DOI怎么找? 1789380
邀请新用户注册赠送积分活动 871691
科研通“疑难数据库(出版商)”最低求助积分说明 802963